BioMarin Pharmaceutical (NASDAQ:BMRN) Given New $114.00 Price Target at Barclays

BioMarin Pharmaceutical (NASDAQ:BMRN) had its target price lifted by investment analysts at Barclays from $111.00 to $114.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The firm currently has an “overweight” rating on the biotechnology company’s stock. Barclays‘s price objective would indicate a potential upside of 107.26% from the stock’s previous close.

A number of other analysts also recently commented on BMRN. HC Wainwright reiterated a “neutral” rating and issued a $60.00 target price on shares of BioMarin Pharmaceutical in a report on Thursday, September 10th. Jefferies Financial Group raised their target price on shares of BioMarin Pharmaceutical from $104.00 to $105.00 and gave the stock a “buy” rating in a report on Monday, August 31st. Oppenheimer lifted their price target on shares of BioMarin Pharmaceutical from $95.00 to $97.00 and gave the stock an “outperform” rating in a research report on Friday, August 7th. Royal Bank Of Canada decreased their price target on shares of BioMarin Pharmaceutical from $66.00 to $62.00 and set a “sector perform” rating on the stock in a research report on Tuesday, July 7th. Finally, William Blair raised BioMarin Pharmaceutical to a “hold” rating in a report on Wednesday, September 23rd. Two research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, BioMarin Pharmaceutical presently has an average rating of “Moderate Buy” and a consensus price target of $88.87.

BioMarin Pharmaceutical Price Performance

NASDAQ:BMRN opened at $55.00 on Wednesday. The company has a quick ratio of 1.32, a current ratio of 2.39 and a debt-to-equity ratio of 0.56. The business’s 50-day moving average price is $63.40 and its 200 day moving average price is $58.67. BioMarin Pharmaceutical has a 52-week low of $49.26 and a 52-week high of $70.98. The firm has a market cap of $10.65 billion, a P/E ratio of 148.63, a PEG ratio of 0.38 and a beta of 0.22.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, beating analysts’ consensus estimates of $0.95 by $0.25. BioMarin Pharmaceutical had a net margin of 2.14% and a return on equity of 5.32%. The company had revenue of $989.71 million during the quarter, compared to the consensus estimate of $932.03 million. During the same period in the prior year, the company earned $1.44 EPS. BioMarin Pharmaceutical’s revenue was up 20.0% on a year-over-year basis. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. As a group, sell-side analysts predict that BioMarin Pharmaceutical will post 4.10 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioMarin Pharmaceutical

A number of institutional investors have recently bought and sold shares of BMRN. Amundi lifted its stake in BioMarin Pharmaceutical by 37.8% during the second quarter. Amundi now owns 259,782 shares of the biotechnology company’s stock valued at $14,865,000 after buying an additional 71,246 shares in the last quarter. Rice Hall James & Associates LLC purchased a new position in shares of BioMarin Pharmaceutical in the second quarter worth approximately $14,203,000. Bank of New York Mellon Corp purchased a new position in shares of BioMarin Pharmaceutical in the second quarter worth approximately $66,107,000. Public Employees Retirement System of Ohio acquired a new stake in shares of BioMarin Pharmaceutical during the second quarter valued at approximately $3,461,000. Finally, Edmond DE Rothschild Holding S.A. acquired a new stake in shares of BioMarin Pharmaceutical during the second quarter valued at approximately $39,312,000. Hedge funds and other institutional investors own 98.71% of the company’s stock.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biotechnology company that develops and commercializes therapies for rare and serious genetic diseases. The company focuses on conditions with limited treatment options, using approaches that include enzyme replacement therapy, small-molecule medicines, biologics and gene therapy.

Its products include Vimizim for mucopolysaccharidosis type IV A, Naglazyme for mucopolysaccharidosis type VI, Brineura for CLN2 disease, Palynziq and Kuvan for phenylketonuria, and Voxzogo for children with achondroplasia and open growth plates.